{{Rsnum
|rsid=8173
|Gene=AURKA
|Chromosome=20
|position=56369735
|Orientation=plus
|GMAF=0.4775
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=AURKA
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 57.7 | 37.8 | 4.5
| HCB | 19.1 | 44.9 | 36.0
| JPT | 13.4 | 50.9 | 35.7
| YRI | 8.8 | 32.7 | 58.5
| ASW | 10.7 | 48.2 | 41.1
| CHB | 19.1 | 44.9 | 36.0
| CHD | 5.6 | 54.2 | 40.2
| GIH | 43.0 | 47.0 | 10.0
| LWK | 4.5 | 44.5 | 50.9
| MEX | 25.9 | 48.3 | 25.9
| MKK | 5.9 | 30.7 | 63.4
| TSI | 52.5 | 38.6 | 8.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=21630024
|Title=Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome
}}

{{PMID|18802780}} Common genetic polymorphisms of AURKA and prostate cancer risk.

{{PMID|19252927|OA=1
}} Bladder cancer SNP panel predicts susceptibility and survival.

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}